Filing Details
Silexion Therapeutics Corp (NASDAQ:SLXN) filed a Form 8-K with the Securities and Exchange Commission on August 14, 2026, disclosing a material event.
8k filedNASDAQ:SLXN
Silexion Therapeutics Corp (SLXN) Reports Material Event to SEC
Silexion Therapeutics Corp (NASDAQ:SLXN) filed a Form 8-K with the Securities and Exchange Commission on August 14, 2026, disclosing a material event.
At publication ·
What changed
Silexion Therapeutics Corp (NASDAQ:SLXN) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- Silexion Therapeutics Corp filed a Form 8-K with the SEC on August 14, 2026, disclosing a material event, though the specific nature of the event is not detailed in this filing summary.
- The company's stock trades at $0.42 per share with a market capitalization of $1.7 million as of the filing date.
- Form 8-K filings are required to disclose material events such as leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance that occur between regular quarterly or annual reports.
Market Context
Silexion Therapeutics Corp's stock currently trades at $0.42 with a market capitalization of $1.7M. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Silexion Therapeutics Corp's stock.
All SEC filings for Silexion Therapeutics Corp are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View SLXN Stock Page
Frequently Asked Questions
Where can I read SLXN's SEC filings?
Browse all filings on our SLXN SEC filings page.
What types of SEC filings does Silexion Therapeutics Corp file?
Public companies like Silexion Therapeutics Corp file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.